Construction and validation of a prediction model for postoperative recurrence risk of cervical high-risk lesions using nomogram analysis

Shuxia Wu, Miaomiao Li, Xingye Ren

Abstract

Patients with cervical high-risk lesions face a heightened risk of recurrence following cervical conization, making early prediction of recurrence essential for effective treatment and follow-up. This retrospective cohort study aimed to develop a recurrence risk prediction model using clinical factors to enhance prediction accuracy and guide clinical decisions. The study included 120 female patients undergoing their first cervical conization with positive surgical margins. Clinical data such as age, human papilloma virus (HPV) typing, surgical margin status, colposcopy results, and postoperative treatments were analyzed. Univariate and multivariate logistic regression identified age ≥ 45 years, HPV 16/18 infection, and positive surgical margins at the internal or external os as independent predictors of recurrence. A nomogram model was constructed and validated externally, achieving 90.3% accuracy in predicting recurrence in an additional 31 patients. Decision curve analysis confirmed the model's higher net benefit compared to single-factor predictions. We conclude that the recurrence risk prediction model, based on age, HPV typing, and surgical margin status, offers high accuracy and clinical utility, supporting individualized patient management and precise treatment planning.

Full Text:

PDF

References

Darragh TM. The LAST Project and the diagnostic bottom

line. Cytopathology. 2015 Dec;26(6):343-5.

Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C and

Basu P. Efficacy and safety of therapeutic HPV

vaccines to treat CIN 2/CIN 3 lesions: a systematic

review and meta-analysis of phase II/III clinical

trials. BMJ Open. 2023 Oct 24;13(10):e069616.

Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH,

Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R,

Saraiya M, Sawaya GF, Wentzensen N and

Schiffman M. 2019 ASCCP risk-based management

consensus guidelines for abnormal cervical cancer

screening tests and cancer precursors. J Low Genit

Tract

Dis.

;24(2):102–131.

doi:10.1097/LGT.0000000000000525

Ma X and Yang M. The correlation between high-risk HPV

infection and precancerous lesions and cervical

cancer. Am J Transl Res. 2021 Sep 15;13(9):10830

Chen R, Zhang R, Zhang M, Liu S, Xie M, Yang Z, Shi Q,

Chen H, Xiong H, Wang N and Jiang Q. CIN grades

possessing different HPV RNA location patterns and

RNAscope is helpful tool for distinguishing

squamous intraepithelial lesions in difficult cervical

cases. Diagn Pathol. 2023 Feb 16;18(1):23.

Yang J and Xue F. Research Progress of Immune

Mechanisms Related to Persistent HPV Infection in

CIN after Cervical Conization. Iran J Allergy

Asthma Immunol. 2024 Oct 6;23(5):467-475.

de Castro CA, Lombardi W, Stringasci MD, Bagnato VS and

Inada NM. High-risk HPV clearance and CIN 3

treated with MAL-PDT: A case report. Photodiagnosis

Photodyn

Ther.

Sep;31:101937. doi: 10.1016/j.pdpdt.2020.101937.

Epub 2020 Jul 30. PMID: 32739622.

Zhang S, Saito M, Yamada S, Sakamoto J, Takakura M,

Takagi H and Sasagawa T. The prevalence of VAIN,

CIN, and related HPV genotypes in Japanese women

with abnormal cytology. J Med Virol. 2020

Mar;92(3):364-371.

Valasoulis G, Michail G, Pouliakis A, Androutsopoulos G,

Panayiotides IG, Kyrgiou M and Daponte A and

Paraskevaidis E. Effect of Condom Use after CIN

Treatment on Cervical HPV Biomarkers Positivity:

Prolonged Follow Up Study. Cancers (Basel). 2022

Jul 20;14(14):3530.

Alrajjal A, Pansare V, Choudhury MSR, Khan MYA and

Shidham VB. Squamous intraepithelial lesions (SIL:

LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine

Cervix and Bethesda System. Cytojournal. 2021 Jul

;18:16.

Parra-Herran C, Nucci MR, Singh N, Rakislova N, Howitt

BE, Hoang L, Gilks CB and Bosse T, Watkins JC.

HPV-independent,

p53-wild-type

vulvar

intraepithelial neoplasia: a review of nomenclature

and the journey to characterize verruciform and

acanthotic precursor lesions of the vulva. Mod

Pathol. 2022 Oct;35(10):1317-1326.

Li A, Li J, Austin RM, Wang T, Ashman D, Zhang H,

Matsko J and Zhao C. Aptima HPV messenger RNA

testing and histopathologic follow-up in women

with HSIL cytology: A study emphasizing

additional review of HPV-negative cases. Cancer

Cytopathol. 2021 Aug;129(8):622-631.

Rakislova N, Alemany L, Clavero O, Del Pino M, Saco A,

Marimon L, Quirós B, Lloveras B, Ribera-Cortada

I, Alejo M, Pawlita M, Quint W, de Sanjose S and

Ordi J; VVAP Study Group. HPV-independent

Precursors Mimicking High-grade Squamous

Intraepithelial Lesions (HSIL) of the Vulva. Am J

Surg Pathol. 2020 Nov;44(11):1506-1514.

Ghelardi A, Marrai R, Bogani G, Sopracordevole F, Bay P,

Tonetti A, Lombardi S, Bertacca G and Joura EA.

Surgical Treatment of Vulvar HSIL: Adjuvant HPV

Vaccine Reduces Recurrent Disease. Vaccines

(Basel). 2021 Jan 25;9(2):83.

Hernandez AL, Weatherly CS, Gonzalez R, Farhat S, Da

Costa M, Calderon J, Kauffman J, Akha AS, Hilton

JF and Palefsky JM. Rationale and design of the

Anal HPV, HIV and Aging (AHHA) study: Protocol

for a prospective study of anal HPV infection and

HSIL among men who have sex (MSM) or trans

women living with and without HIV, ages 50 and

older. Front Epidemiol. 2022 Nov 16;2:992718.

Ashman D, Zhang H, Li J, Austin M, Wang T, Pradhan D

and Zhao C. HPV detection rates and

histopathologic follow-up of patients with HSIL

cytology in a large academic women's hospital

laboratory. J Am Soc Cytopathol. 2020 Nov

Dec;9(6):550-555.

Reich O, Regauer S and Kashofer K. Possibly carcinogenic

HPV subtypes are a cause of HSIL and negative

clinical HPV tests - A European prospective single

center study. Gynecol Oncol. 2020 Jul;158(1):112

Ramos-Cartagena JM, Keller K, Guiot HM, Muñoz C,

Colón-López V, Deshmukh AA, Suárez EL, Tirado

Gómez M and Ortiz AP. Evaluating the performance

of anal cytology and high-risk HPV genotyping for

detecting anal HSIL in a clinic-based sample of

people living with and without HIV in Puerto Rico.

Cancer Cytopathol. 2023 Oct;131(10):655-664.

García-Martínez CM, Calle-Gómez I, López-Hidalgo J,

Gómez-Ronquillo P, Omar-Mohamed Balgahata M

and Hidalgo-Tenorio C. Role of Low-Risk HPV

PCR Monoinfection in Screening for HSIL and Anal

Cancer in Men Who Have Sex with Men Living with

HIV. Int J Mol Sci. 2023 Mar 15;24(6):5642.

Wang T, Zhang H, Liu Y and Zhao C. Updates in Cervical

Cancer Screening Guidelines, The Bethesda System

for Reporting Cervical Cytology, and Clinical

Management Recommendations. J Clin Transl

Pathol. 2023 Jun;3(2):75-83. 21. Van Keer S,

Latsuzbaia A, Broeck DV, De Sutter P, Donders G,

Doyen J, Tjalma WAA, Weyers S, Arbyn M,

Vorsters A. Equivalent Clinical Accuracy of Human

Papillomavirus DNA Testing Using Cobas 4800 and

Human Papillomavirus Systems in Paired

Urine and Cervical Samples. J Mol Diagn. 2025 Mar

:S1525-1578(25)00060-1.

Han L and Zhang B. Can prophylactic HPV vaccination

reduce the recurrence of cervical lesions after

surgery? Review and prospect. Infect Agent Cancer.

Oct 29;18(1):66.

Kulkarni A, Covens A, Durand N, Ghorab Z, Gien LT,

Osborne R, Vicus D and Kupets R. Role of HPV in

the Prediction of Persistence/Recurrence After

Treatment for Cervical Precancer. J Obstet

Gynaecol Can. 2023 Oct;45(10):102171.

Zhang Y, Zou J, Li L, Han M, Dong J and Wang X.

Comprehensive assessment of postoperative

recurrence and survival in patients with cervical

cancer. Eur J Surg Oncol. 2024 Oct;50(10):108583.

Refbacks

  • There are currently no refbacks.